Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

Elligo Launches Expanded System of Accelerated Research (SOARtm)


Elligo Health Research®, a healthcare-enabling research organization, is launching their fully realized System of Accelerated Research (SOAR) model for decentralized (DCTs) and hybrid trial models with fully remote monitoring capabilities.

Only Elligo has developed as a continuum of technologies and data science capabilities; Elligo's SOARtm model expands patient access to reach diverse patient populations that typically don't have access to clinical research as a care option. The solution drives efficiency by enabling direct data from source to submission and full remote site access, empowering patients, physicians, and sponsors to conduct more trials efficiently and faster in traditional and decentralized models.

"We are extremely excited to launch our tech-enabled solution created to keep the patient and the physician at the heart of its design, while providing sponsors transparency," said John Potthoff, Ph.D., CEO of Elligo. "Our goal has always been to provide all patients with access to research as a healthcare option, which is important now more than ever as we navigate the future of clinical research."

SOAR not only mitigates risk, but adheres to regulations and improves data quality while decreasing resource requirements and costs associated with clinical research. Paired with technology-enabled services and expert personnel, this model accelerates research without compromising quality and integrity. This provides a pathway to either use traditional research sites, DCTs, or hybrid trials, seamlessly moving between options without causing disruption for any stakeholders. This modernizes clinical research for a new paradigm in a new age of clinical research.

About Elligo Health Research®

Elligo Health Research, a healthcare-enabling research organization, uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by our Goes Direct® approach and novel IntElligo® Research Stack clinical technology, our team provides access to the best healthcare experts, patients, and research technologies. We engage physicians and patients who otherwise would not participate in clinical research and accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Learn more at elligodirect.com.


These press releases may also interest you

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...

at 15:55
Valley Mountain Regional Center ("VMRC") experienced a data security incident that involved personal and / or protected health information belonging to certain current and former patients and has provided notice of this incident to impacted...



News published on and distributed by: